Open AccessRare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy
Author(s) -
Murat Sarı,
Adnan Aydıner
Publication year - 2020
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_757_19
Subject(s) - erlotinib , epidermal growth factor receptor , medicine , lung cancer , oncology , gefitinib , erlotinib hydrochloride , cancer research , adenocarcinoma , egfr inhibitors , tyrosine kinase , cancer , receptor
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be effective treatments for advanced NSCLC patients with sensitizing EGFR mutations. There are many complex and rare mutations in the EGFR gene. The efficacy of the first-generation EGFR-TKI (erlotinib) is unknown for tumors harboring rare EGFR mutations.